Infectious hepatitis e virus genotype 3 recombinants
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Serv, Royal Cornwall Hospital Trust
InventorsSuzanne U. Emerson, Priyanka Shukla, Hanh T. Nguyen, Robert H. Purcell, Harry R. Dalton, Richard Bendall
Life of this patent
Estimating the term…
Abstract
The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus.
Claims18
An infectious hepatitis E virus (HEV) type 3 cDNA clone, wherein the infectious clone comprises an insert, relative to the HEV nucleic acid sequence set forth in SEQ ID NO:5, in the region of the nucleic acid sequence that encodes the hypervariable region of ORF1, wherein the insert encodes a polypeptide of 20 to 100 amino acids in length having at least 85% identity to a human ribosomal protein.
An infectious hepatitis E virus (HEV) cDNA clone, wherein the cDNA clone has at least 75% sequence identity to SEQ ID NO:1 and comprises an insert in the region of the nucleic acid sequence that encodes the hypervariable region of ORF1, relative to the HEV nucleic acid sequence set forth in SEQ ID NO:5, wherein the insert comprises a region of 20 to 100 amino acids in length that has at least 85% identity to a human ribosomal protein.
An infectious hepatitis E virus genotype 1 cDNA clone comprising a hepatitis E virus (HEV) nucleic acid sequence, wherein the infectious clone comprises an insert in the region of the nucleic acid sequence that encodes the hypervariable region of ORF1, wherein the insert encodes a polypeptide of 20 to 100 amino acids in length having at least 85% identity to a human ribosomal protein.
A method of assessing the virus status of a product of interest subjected to a virus treatment process, the method comprising:
- adding HEV virus produced using a cDNA clone of caim 1 into the product;
- subjecting the product to a virus treatment process that removes and/or inactivates virus present in the product;
- and
- determining the level of added virus in the product remaining after or during the virus treatment process.
Dependencies are inferred from the claim text.